Skip to content

Advertisement

BMC Cancer

What do you think about BMC? Take part in

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors

  • Patricia M. LoRusso1Email author,
  • Jeffrey R. Infante2, 3,
  • Kevin B. Kim4,
  • Howard A. BurrisIII2, 3,
  • Gregory Curt^5,
  • Ugochi Emeribe5,
  • Delyth Clemett6,
  • Helen K. Tomkinson6 and
  • Roger B. Cohen7
^Deceased
BMC Cancer201717:173

https://doi.org/10.1186/s12885-017-3143-6

Received: 19 August 2016

Accepted: 15 February 2017

Published: 6 March 2017

Back to article

Open Peer Review reports

Pre-publication versions of this article and author comments to reviewers are available by contacting info@biomedcentral.com.

Original Submission
19 Aug 2016 Submitted Original manuscript
30 Aug 2016 Author responded Author comments - Patricia M LoRusso
Resubmission - Version 2
30 Aug 2016 Submitted Manuscript version 2
23 Sep 2016 Reviewed Reviewer Report - Roberto Passera
23 Sep 2016 Reviewed Reviewer Report - Nagio Takigawa
21 Dec 2016 Author responded Author comments - Patricia M LoRusso
Resubmission - Version 3
21 Dec 2016 Submitted Manuscript version 3
12 Jan 2017 Author responded Author comments - Patricia M LoRusso
Resubmission - Version 4
12 Jan 2017 Submitted Manuscript version 4
Publishing
15 Feb 2017 Editorially accepted
6 Mar 2017 Article published 10.1186/s12885-017-3143-6

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article and author comments to reviewers are available by contacting info@biomedcentral.com. All previous versions of the manuscript and all author responses to the reviewers are also available.

You can find further information about the peer review system here.

Authors’ Affiliations

(1)
Yale Cancer Center
(2)
Sarah Cannon Research Institute
(3)
Tennessee Oncology PLLC
(4)
California Pacific Medical Center
(5)
AstraZeneca
(6)
AstraZeneca
(7)
Fox Chase Cancer Center

Advertisement